Pharmaceutical composition for treating FLT3 mutation-positive cancer, mutant FLT3 inhibitor and uses thereof


Ontology type: sgo:Patent     


Patent Info

DATE

2018-06-05T00:00

AUTHORS

Tomoki Naoe , Hitoshi Kiyoi , Shinji Hagiwara , Masaru Takasaki , Daisuke Hirano , Toshiyuki NAKATANI , Takeshi Yamaura

ABSTRACT

Provided are a pharmaceutical composition for treating an FLT3 mutation-positive cancer; a mutant FLT3 inhibitor; and uses thereof. Disclosed are a pharmaceutical composition for treating an FLT3 mutation-positive cancer, containing a compound represented by General Formula [1] or a salt thereof as an active ingredient; a mutant FLT3 inhibitor; an anticancer agent; a method for predicting a therapeutic effect by administration of a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof in a subject, including a step of detecting the presence or absence of an FLT3 mutation; a method for selecting a subject to whom a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is applied, including a step of detecting the presence or absence of an FLT3 mutation; and a method for determining whether or not a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is administered to a subject, including a step of detecting the presence or absence of an FLT3 mutation. More... »

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "Tomoki Naoe", 
        "type": "Person"
      }, 
      {
        "name": "Hitoshi Kiyoi", 
        "type": "Person"
      }, 
      {
        "name": "Shinji Hagiwara", 
        "type": "Person"
      }, 
      {
        "name": "Masaru Takasaki", 
        "type": "Person"
      }, 
      {
        "name": "Daisuke Hirano", 
        "type": "Person"
      }, 
      {
        "name": "Toshiyuki NAKATANI", 
        "type": "Person"
      }, 
      {
        "name": "Takeshi Yamaura", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1182/blood-2002-02-0492", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006937015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2400812", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025757807", 
          "https://doi.org/10.1038/sj.leu.2400812"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2400812", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025757807", 
          "https://doi.org/10.1038/sj.leu.2400812"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.11201", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026332476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2004-07-2942", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027038954"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0378-5173(94)90104-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034725348"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0378-5173(94)90104-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034725348"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2402740", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041582176", 
          "https://doi.org/10.1038/sj.leu.2402740"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2402740", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041582176", 
          "https://doi.org/10.1038/sj.leu.2402740"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1205332", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042923053", 
          "https://doi.org/10.1038/sj.onc.1205332"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1205332", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042923053", 
          "https://doi.org/10.1038/sj.onc.1205332"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-04-2148", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049668651"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2009-09-242859", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051282719"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/op000018u", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056286499"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/op000018u", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056286499"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-06-05T00:00", 
    "description": "

Provided are a pharmaceutical composition for treating an FLT3 mutation-positive cancer; a mutant FLT3 inhibitor; and uses thereof. Disclosed are a pharmaceutical composition for treating an FLT3 mutation-positive cancer, containing a compound represented by General Formula [1] or a salt thereof as an active ingredient; a mutant FLT3 inhibitor; an anticancer agent; a method for predicting a therapeutic effect by administration of a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof in a subject, including a step of detecting the presence or absence of an FLT3 mutation; a method for selecting a subject to whom a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is applied, including a step of detecting the presence or absence of an FLT3 mutation; and a method for determining whether or not a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is administered to a subject, including a step of detecting the presence or absence of an FLT3 mutation.

\"embedded

", "id": "sg:patent.US-9987278-B2", "keywords": [ "pharmaceutical", "FLT3 mutation", "FLT3 inhibitor", "compound", "general formula", "salt", "active ingredient", "anticancer agent", "method", "therapeutic effect", "Organization and Administration", "absence" ], "name": "Pharmaceutical composition for treating FLT3 mutation-positive cancer, mutant FLT3 inhibitor and uses thereof", "recipient": [ { "id": "https://www.grid.ac/institutes/grid.410862.9", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/US-9987278-B2" ], "sdDataset": "patents", "sdDatePublished": "2019-04-18T10:22", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-uberresearch-data-patents-target-20190320-rc/data/sn-export/402f166718b70575fb5d4ffe01f064d1/0000100128-0000352499/json_export_01762.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.US-9987278-B2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.US-9987278-B2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.US-9987278-B2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.US-9987278-B2'


 

This table displays all metadata directly associated to this object as RDF triples.

91 TRIPLES      15 PREDICATES      36 URIs      20 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.US-9987278-B2 schema:about anzsrc-for:3142
2 schema:author Ncbc92b65a1b64f2b9241cd37f6d76461
3 schema:citation sg:pub.10.1038/sj.leu.2400812
4 sg:pub.10.1038/sj.leu.2402740
5 sg:pub.10.1038/sj.onc.1205332
6 https://doi.org/10.1016/0378-5173(94)90104-x
7 https://doi.org/10.1021/op000018u
8 https://doi.org/10.1158/0008-5472.can-04-2148
9 https://doi.org/10.1182/blood-2002-02-0492
10 https://doi.org/10.1182/blood-2004-07-2942
11 https://doi.org/10.1182/blood-2009-09-242859
12 https://doi.org/10.3324/haematol.11201
13 schema:datePublished 2018-06-05T00:00
14 schema:description <p id="p-0001" num="0000">Provided are a pharmaceutical composition for treating an FLT3 mutation-positive cancer; a mutant FLT3 inhibitor; and uses thereof. Disclosed are a pharmaceutical composition for treating an FLT3 mutation-positive cancer, containing a compound represented by General Formula [1] or a salt thereof as an active ingredient; a mutant FLT3 inhibitor; an anticancer agent; a method for predicting a therapeutic effect by administration of a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof in a subject, including a step of detecting the presence or absence of an FLT3 mutation; a method for selecting a subject to whom a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is applied, including a step of detecting the presence or absence of an FLT3 mutation; and a method for determining whether or not a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is administered to a subject, including a step of detecting the presence or absence of an FLT3 mutation.</p><p id="p-0002" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="32.77mm" wi="76.03mm" file="US09987278-20180605-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif" orientation="portrait" inline="no"/><attachments><attachment idref="CHEM-US-00001" attachment-type="cdx" file="US09987278-20180605-C00001.CDX"/><attachment idref="CHEM-US-00001" attachment-type="mol" file="US09987278-20180605-C00001.MOL"/></attachments></chemistry></p>
15 schema:keywords FLT3 inhibitor
16 FLT3 mutation
17 Organization and Administration
18 absence
19 active ingredient
20 anticancer agent
21 compound
22 general formula
23 method
24 pharmaceutical
25 salt
26 therapeutic effect
27 schema:name Pharmaceutical composition for treating FLT3 mutation-positive cancer, mutant FLT3 inhibitor and uses thereof
28 schema:recipient https://www.grid.ac/institutes/grid.410862.9
29 schema:sameAs https://app.dimensions.ai/details/patent/US-9987278-B2
30 schema:sdDatePublished 2019-04-18T10:22
31 schema:sdLicense https://scigraph.springernature.com/explorer/license/
32 schema:sdPublisher Nb5022ff6b90e4e60bb97ee5db2fceace
33 sgo:license sg:explorer/license/
34 sgo:sdDataset patents
35 rdf:type sgo:Patent
36 N1518b32d205b4beea9484db9584b0072 rdf:first N58f86dd2fc0548c5a40eb2fbcfb6812b
37 rdf:rest Na2f8fb46e4ab4f77888cc1bf5a98112c
38 N1c81323f9271438e81c8ea9e658a516f rdf:first N5f229c475a73477e9633fb11a1294079
39 rdf:rest Nf237a1becc5145c4a1285b1bfbf18f43
40 N1eff7252fde445f5b667202788627b99 schema:name Takeshi Yamaura
41 rdf:type schema:Person
42 N58f86dd2fc0548c5a40eb2fbcfb6812b schema:name Shinji Hagiwara
43 rdf:type schema:Person
44 N5f229c475a73477e9633fb11a1294079 schema:name Daisuke Hirano
45 rdf:type schema:Person
46 N81948104c8f343629ab864bc3c10f4b7 schema:name Masaru Takasaki
47 rdf:type schema:Person
48 N8624aa9bcfd44e61b58b1b6aa16ca23e rdf:first N1eff7252fde445f5b667202788627b99
49 rdf:rest rdf:nil
50 N996c205ad3224540919d97f9e5cb7443 schema:name Toshiyuki NAKATANI
51 rdf:type schema:Person
52 N99efd92d539743cd90183397ea487a29 rdf:first Na1080ef7ec234f5da929b203214b4a5e
53 rdf:rest N1518b32d205b4beea9484db9584b0072
54 Na1080ef7ec234f5da929b203214b4a5e schema:name Hitoshi Kiyoi
55 rdf:type schema:Person
56 Na2f8fb46e4ab4f77888cc1bf5a98112c rdf:first N81948104c8f343629ab864bc3c10f4b7
57 rdf:rest N1c81323f9271438e81c8ea9e658a516f
58 Nb5022ff6b90e4e60bb97ee5db2fceace schema:name Springer Nature - SN SciGraph project
59 rdf:type schema:Organization
60 Ncbc92b65a1b64f2b9241cd37f6d76461 rdf:first Nf94f136598814c9eab6c96695122eed9
61 rdf:rest N99efd92d539743cd90183397ea487a29
62 Nf237a1becc5145c4a1285b1bfbf18f43 rdf:first N996c205ad3224540919d97f9e5cb7443
63 rdf:rest N8624aa9bcfd44e61b58b1b6aa16ca23e
64 Nf94f136598814c9eab6c96695122eed9 schema:name Tomoki Naoe
65 rdf:type schema:Person
66 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
67 rdf:type schema:DefinedTerm
68 sg:pub.10.1038/sj.leu.2400812 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025757807
69 https://doi.org/10.1038/sj.leu.2400812
70 rdf:type schema:CreativeWork
71 sg:pub.10.1038/sj.leu.2402740 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041582176
72 https://doi.org/10.1038/sj.leu.2402740
73 rdf:type schema:CreativeWork
74 sg:pub.10.1038/sj.onc.1205332 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042923053
75 https://doi.org/10.1038/sj.onc.1205332
76 rdf:type schema:CreativeWork
77 https://doi.org/10.1016/0378-5173(94)90104-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1034725348
78 rdf:type schema:CreativeWork
79 https://doi.org/10.1021/op000018u schema:sameAs https://app.dimensions.ai/details/publication/pub.1056286499
80 rdf:type schema:CreativeWork
81 https://doi.org/10.1158/0008-5472.can-04-2148 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049668651
82 rdf:type schema:CreativeWork
83 https://doi.org/10.1182/blood-2002-02-0492 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006937015
84 rdf:type schema:CreativeWork
85 https://doi.org/10.1182/blood-2004-07-2942 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027038954
86 rdf:type schema:CreativeWork
87 https://doi.org/10.1182/blood-2009-09-242859 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051282719
88 rdf:type schema:CreativeWork
89 https://doi.org/10.3324/haematol.11201 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026332476
90 rdf:type schema:CreativeWork
91 https://www.grid.ac/institutes/grid.410862.9 schema:Organization
 




Preview window. Press ESC to close (or click here)


...